Contact
searchSearch
HMP Global
Login
GPRC5D
Biological Pathway Review
GPRC5D Expressions in Cancer

Multiple Myeloma

GPRC5D is expressed on CD138+ cells and a target for immunotherapy.1 It is also a promising marker for monitoring the tumor load and targeting multiple myeloma cells since it is highly expressed in these cells, but minimally expressed in other cancer cell types.3

GPRC5D Biological Pathways Reviews

GPRC5D

G protein-coupled receptor class C group 5 member D (GPRC5D) is a gene expressed in the hair follicle and malignant bone marrow plasma cells.1 G protein-coupled receptor proteins are cell surface receptors located in the plasma membrane. Activation of the protein occurs when it binds to an external signaling molecule, which causes a conformational change and triggers an interaction between the protein and an available G protein.2

Understanding the Role of GPRC5D

Videos

Sundar Jagannath, MD, Mount Sinai
Videos
Bispecific Antibodies, CAR T-Cell Therapy, and BCMA-Directed Therapy for the Treatment of Multiple Myeloma With Curative Intent
02/23/2023
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
Sundar Jagannath, MD, provides...
02/23/2023
Oncology
Dan Vogl, MD, University of Pennsylvania
Videos
Bispecific T-Cell Engagers and Novel Approaches for the Treatment of Multiple Myeloma
02/23/2023
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options...
02/23/2023
Oncology
Faith Davies, MD
Videos
What Is the Optimal Combination for Patients With Multiple Myeloma in Early Relapse?
02/16/2023
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an...
02/16/2023
Oncology
Ajai Chari, MD
Videos
Expedited FDA Approval of Teclistamab for Relapsed/Refractory Multiple Myeloma
02/05/2023
Ajai Chari, MD, provides insight into the FDA approval of teclistamab for relapsed/refractory multiple myeloma and background on the data that led to this approval.
Ajai Chari, MD, provides insight into the FDA approval of teclistamab for relapsed/refractory multiple myeloma and background on the data that led to this approval.
Ajai Chari, MD, provides insight...
02/05/2023
Oncology
Shaji K. Kumar, MD
Videos
Daratumumab Plus Lenalidomide and Dexamethasone Demonstrates Survival Benefits for Transplant-Ineligible Patients With Newly Diagnosed MM
02/05/2023
Shaji K. Kumar, MD, discusses the PFS and OS benefit seen with daratumumab added to lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in transplant-ineligible patients with newly diagnosed multiple myeloma.
Shaji K. Kumar, MD, discusses the PFS and OS benefit seen with daratumumab added to lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in transplant-ineligible patients with newly diagnosed multiple myeloma.
Shaji K. Kumar, MD, discusses...
02/05/2023
Oncology
Shaji Kumar, MD
Videos
Strategies for Treating Frail and Transplant-Ineligible Patients With Multiple Myeloma
01/26/2023
Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.
Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.
Shaji Kumar, MD, provides...
01/26/2023
Oncology
Ajari Chari, MD
Videos
Talquetamab Demonstrates Robust Efficacy, Manageable Safety in Patients With Heavily Pretreated R/R Multiple Myeloma
12/12/2022
At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.
At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.
At the 2022 ASH Annual Meeting...
12/12/2022
Oncology
Emese Zsiros, MD, PhD
Videos
Pembrolizumab Plus Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
04/24/2026
Emese Zsiros, MD, PhD, discusses results from the phase 3 KEYNOTE-B96 trial, which demonstrated that pembrolizumab improves survival while maintaining quality of life in patients with platinum-resistant ovarian cancer.
Emese Zsiros, MD, PhD, discusses results from the phase 3 KEYNOTE-B96 trial, which demonstrated that pembrolizumab improves survival while maintaining quality of life in patients with platinum-resistant ovarian cancer.
Emese Zsiros, MD, PhD, discusses...
04/24/2026
Oncology
Videos
Tumor Microenvironment Challenges in Refractory Metastatic Colorectal Cancer (mCRC): An Expert Debate
04/23/2026
Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD
The management of refractory metastatic colorectal cancer (mCRC) remains constrained by a biologically resistant, immune-excluded tumor microenvironment. In this peer-led debate, experts examine how tumor...
The management of refractory metastatic colorectal cancer (mCRC) remains constrained by a biologically resistant, immune-excluded tumor microenvironment. In this peer-led debate, experts examine how tumor...
The management...
04/23/2026
Oncology
Videos
Round 1: Do Current Therapies Biologically Alter Refractory mCRC?
04/23/2026
Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD
04/23/2026
Oncology
Videos
Round 2: Are We Adequately Targeting the TME in mCRC?
04/23/2026
Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD
04/23/2026
Oncology
Videos
Round 3: Are We Adequately Stratifying mCRC Tumors to Inform Therapy?
04/23/2026
Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD
04/23/2026
Oncology
Videos
Introduction: Are We Meaningfully Impacting the Tumor Microenvironment?
04/22/2026
Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD
04/22/2026
Oncology
Sikander Ailawadhi, MD
Videos
Emerging Therapeutic Options for Patients With Relapsed/Refractory Multiple Myeloma
04/21/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses the rapidly evolving treatment landscape for patients with multiple myeloma.
Sikander Ailawadhi, MD, discusses the rapidly evolving treatment landscape for patients with multiple myeloma.
Sikander Ailawadhi, MD,...
04/21/2026
Oncology
Michael Wang, MD
Videos
FDA Approves Brexucabtagene Autoleucel for Patients With R/R Mantle Cell Lymphoma
04/21/2026
Michael Wang, MD
Michael Wang, MD, discusses the recent FDA approval of brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma.
Michael Wang, MD, discusses the recent FDA approval of brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma.
Michael Wang, MD, discusses the...
04/21/2026
Oncology
Javier Pinilla Ibarz, MD, PhD
Videos
Evolving Role of CAR-T and Bispecific Therapies in Chronic Lymphocytic Leukemia
04/21/2026
Javier Pinilla-Ibarz, MD, PhD
Javier Pinilla Ibarz, MD, PhD, discusses the evolving role of CAR T-cell therapy and bispecific antibodies in chronic lymphocytic leukemia.
Javier Pinilla Ibarz, MD, PhD, discusses the evolving role of CAR T-cell therapy and bispecific antibodies in chronic lymphocytic leukemia.
Javier Pinilla Ibarz, MD, PhD,...
04/21/2026
Oncology
Justin Taylor, MD
Videos
Next-Generation BTK Degraders for Patients With Chronic Lymphocytic Leukemia
04/21/2026
Justin Taylor, MD
Justin Taylor, MD, discusses the emerging role of Bruton's tyrosine kinase degrader therapies in chronic lymphocytic leukemia.
Justin Taylor, MD, discusses the emerging role of Bruton's tyrosine kinase degrader therapies in chronic lymphocytic leukemia.
Justin Taylor, MD, discusses the...
04/21/2026
Oncology

Resources

News
GPRC5D-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
03/23/2023
Amber Denham
Phase 1 results from the POLARIS trial demonstrate that GPRC5D-targeted CAR-T cell therapy (OriCAR-017) is a promising treatment modality for patients with relapsed/refractory multiple myeloma.
Phase 1 results from the POLARIS trial demonstrate that GPRC5D-targeted CAR-T cell therapy (OriCAR-017) is a promising treatment modality for patients with relapsed/refractory multiple myeloma.
Phase 1 results from the POLARIS...
03/23/2023
Oncology
News
Promising Clinical Efficacy for GPRC5D-Targeting CAR-T Cell Therapy in R/R Multiple Myeloma
03/23/2023
Amber Denham
GPRC5D-targeting CAR-T cell therapy demonstrated a promising clinical efficacy and manageable safety profile in patients with relapsed/refractory multiple myeloma.
GPRC5D-targeting CAR-T cell therapy demonstrated a promising clinical efficacy and manageable safety profile in patients with relapsed/refractory multiple myeloma.
GPRC5D-targeting CAR-T cell...
03/23/2023
Oncology
News
Talquetamab Shows Promise as Novel Agent for Patients With Multiple Myeloma
06/20/2022
Yvette C. Terrie, BS Pharm, RPh
Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.
Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.
Study findings show the novel...
06/20/2022
Oncology
News
Study Highlights Need for New Treatment Approaches, Novel Therapies for Relapsed/Refractory MM
05/11/2022
John Otrompke, BA, JD
Findings from the LocoMMotion study demonstrate there is no well-established standard of care treatment for patients with triple-class exposed relapsed/refractory MM.
Findings from the LocoMMotion study demonstrate there is no well-established standard of care treatment for patients with triple-class exposed relapsed/refractory MM.
Findings from the LocoMMotion...
05/11/2022
Oncology
News
Isatuximab Plus Pomalidomide and Dexamethasone: New Standard of Care for Relapsed/Refractory MM
03/02/2022
John Otrompke, BA, JD
A novel combination of isatuximab plus standard of care pomalidomide and dexamethasone resulted in improved OS for patients with R/R MM, according to the phase 3 ICARIA-MM trial.
A novel combination of isatuximab plus standard of care pomalidomide and dexamethasone resulted in improved OS for patients with R/R MM, according to the phase 3 ICARIA-MM trial.
A novel combination of...
03/02/2022
Oncology
News
Teclistamab Shows Durable Responses in Heavily Pretreated Patients With R/R MM
01/27/2022
Teclistamab showed robust safety data as a BCMA and CD3 bispecific antibody during the MajesTEC-1 trial to treat patients with heavily pretreated R/R MM.
Teclistamab showed robust safety data as a BCMA and CD3 bispecific antibody during the MajesTEC-1 trial to treat patients with heavily pretreated R/R MM.
Teclistamab showed robust safety...
01/27/2022
Oncology
News
Lorlatinib Shows Real-World Promise in in ALK-Positive Non-Small Cell Lung Cancer
04/24/2026
Emily Estrada
Real-world data demonstrate that lorlatinib provides high response and durable disease control in advanced ALK-positive NSCLC, with exploratory lipid biomarkers potentially predicting response.
Real-world data demonstrate that lorlatinib provides high response and durable disease control in advanced ALK-positive NSCLC, with exploratory lipid biomarkers potentially predicting response.
Real-world data demonstrate that...
04/24/2026
Oncology
News
Mirvetuximab Plus Carboplatin Demonstrates Promise in Platinum-Sensitive Ovarian Cancer
04/21/2026
Stephanie Holland
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2...
04/21/2026
Oncology
News
Mocertatug Rezetecan Shows Promising Efficacy, Manageable Safety in Ovarian and Endometrial Cancer
04/21/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1...
04/21/2026
Oncology
News
Camizestrant Plus Capivasertib Shows Promise in ER-Positive, HER2-Negative Advanced Breast Cancer
04/17/2026
Emily Estrada
Results from the SERENA-1 trial demonstrate that camizestrant plus capivasertib shows strong clinical promise in endocrine-resistant patients with ER-positive, HER2-negative advanced breast cancer.
Results from the SERENA-1 trial demonstrate that camizestrant plus capivasertib shows strong clinical promise in endocrine-resistant patients with ER-positive, HER2-negative advanced breast cancer.
Results from the SERENA-1 trial...
04/17/2026
Oncology
News
R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
LB-100 Plus Dostarlimab Shows Clinical Promise in Platinum-Resistant Ovarian Clear Cell Carcinoma
04/15/2026
Emily Estrada
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase...
04/15/2026
Oncology
News
Longitudinal ctDNA Clearance Predicts Outcomes in Advanced Ovarian Cancer
04/15/2026
Emily Estrada
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective...
04/15/2026
Oncology
News
Chemotherapy Followed by Letrozole Maintains Advantage Over Letrozole Alone in Low-Grade Serous Carcinoma
04/14/2026
Stephanie Holland
Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.
Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.
Results from the phase 3...
04/14/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
04/13/2026
Stephanie Holland
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results...
04/13/2026
Oncology
News
Maintenance Carfilzomib Plus Lenalidomide and Dexamethasone Following Autologous HSCT for Newly Diagnosed Multiple Myeloma
04/10/2026
Stephanie Holland
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS...
04/10/2026
Oncology

Quizzes

Quiz
Quiz: Where is the GPRC5D Gene Expressed?
03/23/2023
True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.
True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.
True or False: The GPRC5D gene...
03/23/2023
Oncology
Quiz
Quiz: Principles Behind Choosing Optimal Therapeutic Agent Combinations for Patients With MM
03/20/2023
According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?
According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?
According to Dr Faith E. Davies,...
03/20/2023
Oncology
Quiz
Sequential Thoracic Radiotherapy After Chemoimmunotherapy in ES-SCLC
04/02/2026
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage...
04/02/2026
Oncology
Quiz
Zanzalintinib Plus Atezolizumab in Relapsed/Refractory Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the...
04/01/2026
Oncology
Quiz
Auceliciclib for Advanced Solid Tumors and Recurrent High-Grade Glioma
03/31/2026
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate...
03/31/2026
Oncology
Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
Serum LDH and α-HBDH Levels in SCLC
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
Quiz
Predictive Accuracy of Whole-Brain Radiotherapy Response in SCLC With Brain Metastases
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology
Quiz
Safusidenib Erbumine for IDH1-Mutated Glioma
03/03/2026
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on...
03/03/2026
Oncology
Quiz
Venetoclax Plus CACAG Therapy for Relapsed/Refractory Acute Myeloid Leukemia
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
Quiz
Oral Iberdomide Combination for R/R MM
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
Quiz
High-Risk Stratification in Cutaneous Squamous Cell Carcinoma
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use